{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:16:30Z","timestamp":1744719390764},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00108-021-01207-6","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T11:02:53Z","timestamp":1635850973000},"page":"1269-1279","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Was ist gesichert in der Therapie chronisch-entz\u00fcndlicher Darmerkrankungen"],"prefix":"10.1007","volume":"62","author":[{"given":"Carolin F.","family":"Manthey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Reher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"issue":"4","key":"1207_CR1","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","volume":"7","author":"J Burisch","year":"2013","unstructured":"Burisch\u00a0J, Jess\u00a0T, Martinato\u00a0M, Lakatos\u00a0PL (2013) ECCO-EpiCom: The burden of inflammatory bowel disease in Europe. J\u00a0Crohn\u2019s Colitis 7(4):322\u2013337","journal-title":"J Crohn\u2019s Colitis"},{"issue":"1","key":"1207_CR2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky\u00a0NA, Soon\u00a0S, Rabi\u00a0DM, Ghali\u00a0WA, Ferris\u00a0M, Chernoff\u00a0G, Benchimol\u00a0EI, Panaccione\u00a0R, Ghosh\u00a0S, Barkema\u00a0HW (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1):46\u201354.e42","journal-title":"Gastroenterology"},{"issue":"10114","key":"1207_CR3","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng\u00a0SC, Shi\u00a0HY, Hamidi\u00a0N, Underwood\u00a0FE, Tang\u00a0W, Benchimol\u00a0EI, Panaccione\u00a0R, Ghosh\u00a0S, Wu\u00a0JC, Chan\u00a0FK (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a\u00a0systematic review of population-based studies. Lancet 390(10114):2769\u20132778","journal-title":"Lancet"},{"key":"1207_CR4","doi-asserted-by":"publisher","DOI":"10.1055\/a-1174-0670","author":"M\u2011T Schnorbach","year":"2020","unstructured":"Schnorbach\u00a0M\u2011T, Kruis\u00a0W (2020) Krankheitskosten chronisch entz\u00fcndlicher Darmerkrankungen in Deutschland. Z\u00a0Gastroenterol. https:\/\/doi.org\/10.1055\/a-1174-0670","journal-title":"Z Gastroenterol"},{"issue":"7","key":"1207_CR5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MCG.0b013e318247c32f","volume":"46","author":"BP Abraham","year":"2012","unstructured":"Abraham\u00a0BP, Mehta\u00a0S, El-Serag\u00a0HB (2012) Natural history of pediatric-onset inflammatory bowel disease: a\u00a0systematic review. J\u00a0Clin Gastroenterol 46(7):581","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"1207_CR6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S2468-1253(20)30012-1","volume":"5","author":"J Burisch","year":"2020","unstructured":"Burisch\u00a0J, Vardi\u00a0H, Schwartz\u00a0D, Friger\u00a0M, Kiudelis\u00a0G, Kup\u010dinskas\u00a0J, Fumery\u00a0M, Gower-Rousseau\u00a0C, Lakatos\u00a0L, Lakatos\u00a0PL (2020) Health-care costs of inflammatory bowel disease in a\u00a0pan-European, community-based, inception cohort during 5\u00a0years of follow-up: a\u00a0population-based study. Lancet Gastroenterol Hepatol 5(5):454\u2013464","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1207_CR7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1146\/annurev-immunol-020711-074937","volume":"30","author":"K Honda","year":"2012","unstructured":"Honda\u00a0K, Littman\u00a0DR (2012) The microbiome in infectious disease and inflammation. Annu Rev Immunol 30:759\u2013795","journal-title":"Annu Rev Immunol"},{"issue":"7285","key":"1207_CR8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature08821","volume":"464","author":"J Qin","year":"2010","unstructured":"Qin\u00a0J, Li\u00a0R, Raes\u00a0J, Arumugam\u00a0M, Burgdorf\u00a0KS, Manichanh\u00a0C, Nielsen\u00a0T, Pons\u00a0N, Levenez\u00a0F, Yamada\u00a0T (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59\u201365","journal-title":"Nature"},{"issue":"1","key":"1207_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12328-017-0813-5","volume":"11","author":"A Nishida","year":"2018","unstructured":"Nishida\u00a0A, Inoue\u00a0R, Inatomi\u00a0O, Bamba\u00a0S, Naito\u00a0Y, Andoh\u00a0A (2018) Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol 11(1):1\u201310","journal-title":"Clin J Gastroenterol"},{"issue":"5","key":"1207_CR10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13238-020-00745-3","volume":"12","author":"S Liu","year":"2021","unstructured":"Liu\u00a0S, Zhao\u00a0W, Lan\u00a0P, Mou\u00a0X (2021) The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. Protein Cell 12(5):331\u2013345","journal-title":"Protein Cell"},{"issue":"8","key":"1207_CR11","first-page":"905","volume":"11","author":"C Maaser","year":"2017","unstructured":"Maaser\u00a0C, Langholz\u00a0E, Gordon\u00a0H, Burisch\u00a0J, Ellul\u00a0P, Ramirez\u00a0VH, Karakan\u00a0T, Katsanos\u00a0KH, Krustins\u00a0E, Levine\u00a0A (2017) European Crohn\u2019s and Colitis Organisation topical review on environmental factors in IBD. J\u00a0Crohns Colitis 11(8):905\u2013920","journal-title":"J Crohns Colitis"},{"issue":"1","key":"1207_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrgastro.2017.136","volume":"15","author":"AN Ananthakrishnan","year":"2018","unstructured":"Ananthakrishnan\u00a0AN, Bernstein\u00a0CN, Iliopoulos\u00a0D, Macpherson\u00a0A, Neurath\u00a0MF, Ali\u00a0RAR, Vavricka\u00a0SR, Fiocchi\u00a0C (2018) Environmental triggers in IBD: a\u00a0review of progress and evidence. Nat Rev Gastroenterol Hepatol 15(1):39\u201349","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"9","key":"1207_CR13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-018-0022-9","volume":"15","author":"H Khalili","year":"2018","unstructured":"Khalili\u00a0H, Chan\u00a0SS, Lochhead\u00a0P, Ananthakrishnan\u00a0AN, Hart\u00a0AR, Chan\u00a0AT (2018) The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 15(9):525\u2013535","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"1207_CR14","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/nu11051111","volume":"11","author":"R Marion-Letellier","year":"2019","unstructured":"Marion-Letellier\u00a0R, Amamou\u00a0A, Savoye\u00a0G, Ghosh\u00a0S (2019) Inflammatory bowel diseases and food additives: to add fuel on the flames! Nutrients 11(5):1111","journal-title":"Nutrients"},{"issue":"1","key":"1207_CR15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000505368","volume":"101","author":"P Schreiner","year":"2020","unstructured":"Schreiner\u00a0P, Martinho-Grueber\u00a0M, Studerus\u00a0D, Vavricka\u00a0SR, Tilg\u00a0H, Biedermann\u00a0L (2020) Nutrition in inflammatory bowel disease. Digestion 101(1):120\u2013135","journal-title":"Digestion"},{"key":"1207_CR16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ntt.2018.04.002","volume":"67","author":"Y Aitbali","year":"2018","unstructured":"Aitbali\u00a0Y, Ba-M\u2019hamed\u00a0S, Elhidar\u00a0N, Nafis\u00a0A, Soraa\u00a0N, Bennis\u00a0M (2018) Glyphosate based-herbicide exposure affects gut microbiota, anxiety and depression-like behaviors in mice. Neurotoxicol Teratol 67:44\u201349","journal-title":"Neurotoxicol Teratol"},{"issue":"2","key":"1207_CR17","first-page":"1","volume":"4","author":"M Kr\u00fcger","year":"2014","unstructured":"Kr\u00fcger\u00a0M, Schledorn\u00a0P, Schr\u00f6dl\u00a0W, Hoppe\u00a0H\u2011W, Lutz\u00a0W, Shehata\u00a0AA (2014) Detection of glyphosate residues in animals and humans. J\u00a0Environ Anal Toxicol 4(2):1\u20135","journal-title":"J Environ Anal Toxicol"},{"issue":"4","key":"1207_CR18","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/e15041416","volume":"15","author":"A Samsel","year":"2013","unstructured":"Samsel\u00a0A, Seneff\u00a0S (2013) Glyphosate\u2019s suppression of cytochrome P450 enzymes and amino acid biosynthesis by the gut microbiome: pathways to modern diseases. Entropy 15(4):1416\u20131463","journal-title":"Entropy"},{"issue":"10","key":"1207_CR19","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/ng.3947","volume":"49","author":"LA Peters","year":"2017","unstructured":"Peters\u00a0LA, Perrigoue\u00a0J, Mortha\u00a0A, Iuga\u00a0A, W\u2011m S, Neiman\u00a0EM, Llewellyn\u00a0SR, Di Narzo\u00a0A, Kidd\u00a0BA, Telesco\u00a0SE (2017) A functional genomics predictive network model identifies regulators of inflammatory bowel disease. Nat Genet 49(10):1437\u20131449","journal-title":"Nat Genet"},{"issue":"1","key":"1207_CR20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coi.2010.12.003","volume":"23","author":"JG Magalhaes","year":"2011","unstructured":"Magalhaes\u00a0JG, Sorbara\u00a0MT, Girardin\u00a0SE, Philpott\u00a0DJ (2011) What is new with Nods? Curr Opin Immunol 23(1):29\u201334","journal-title":"Curr Opin Immunol"},{"issue":"7539","key":"1207_CR21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","volume":"518","author":"KK Farh","year":"2015","unstructured":"Farh\u00a0KK, Marson\u00a0A, Zhu\u00a0J, Kleinewietfeld\u00a0M, Housley\u00a0WJ, Beik\u00a0S, Shoresh\u00a0N, Whitton\u00a0H, Ryan\u00a0RJ, Shishkin\u00a0AA et\u00a0al (2015) Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518(7539):337\u2013343","journal-title":"Nature"},{"key":"1207_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7247238","author":"Q Guan","year":"2019","unstructured":"Guan\u00a0Q (2019) A\u00a0comprehensive review and update on the pathogenesis of inflammatory bowel disease. J\u00a0Immunol Res. https:\/\/doi.org\/10.1155\/2019\/7247238","journal-title":"J Immunol Res"},{"key":"1207_CR23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-6548-9_2","volume":"1514","author":"N Gagliani","year":"2017","unstructured":"Gagliani\u00a0N, Huber\u00a0S (2017) Basic aspects of T helper cell differentiation. Methods Mol Biol 1514:19\u201330","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1207_CR24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MIB.0000000000000955","volume":"23","author":"MC Choy","year":"2017","unstructured":"Choy\u00a0MC, Visvanathan\u00a0K, De Cruz\u00a0P (2017) An overview of the innate and adaptive immune system in inflammatory bowel disease. Inflamm Bowel Dis 23(1):2\u201313","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"1207_CR25","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka\u00a0SR, Schoepfer\u00a0A, Scharl\u00a0M, Lakatos\u00a0PL, Navarini\u00a0A, Rogler\u00a0G (2015) Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 21(8):1982\u20131992","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"1207_CR26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","volume":"105","author":"L Peyrin-Biroulet","year":"2010","unstructured":"Peyrin-Biroulet\u00a0L, Loftus\u00a0EV Jr, Colombel\u00a0J\u2011F, Sandborn\u00a0WJ (2010) The natural history of adult Crohn\u2019s disease in population-based cohorts. Am J Gastroenterol 105(2):289\u2013297","journal-title":"Am J Gastroenterol ."},{"key":"1207_CR27","doi-asserted-by":"publisher","DOI":"10.1055\/a-1296-3444","author":"T Kucharzik","year":"2020","unstructured":"Kucharzik\u00a0T, Dignass\u00a0AU, Atreya\u00a0R, Bokemeyer\u00a0B, Esters\u00a0P, Herrlinger\u00a0K, Kannengiesser\u00a0K, Kienle\u00a0P, Langhorst\u00a0J, Luegering\u00a0A (2020) Updated S3 Guideline ulcerative Colitis-Living Guideline-August 2020-AWMF Registration Number: 021-009. Z\u00a0Gastroenterol. https:\/\/doi.org\/10.1055\/a-1296-3444","journal-title":"Z Gastroenterol"},{"issue":"12","key":"1207_CR28","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","volume":"14","author":"JD Lewis","year":"2008","unstructured":"Lewis\u00a0JD, Chuai\u00a0S, Nessel\u00a0L, Lichtenstein\u00a0GR, Aberra\u00a0FN, Ellenberg\u00a0JH (2008) Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 14(12):1660\u20131666","journal-title":"Inflamm Bowel Dis"},{"key":"1207_CR29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best\u00a0WR, Becktel\u00a0JM, Singleton\u00a0JW et\u00a0al (1976) Development of a\u00a0Crohn\u2019s disease activity index. Gastroenterology 70:439\u2013444","journal-title":"Gastroenterology"},{"issue":"4","key":"1207_CR30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","volume":"60","author":"M Daperno","year":"2004","unstructured":"Daperno\u00a0M, D\u2019Haens\u00a0G, Van Assche\u00a0G, Baert\u00a0F, Bulois\u00a0P, Maunoury\u00a0V, Sostegni\u00a0R, Rocca\u00a0R, Pera\u00a0A, Gevers\u00a0A (2004) Development and validation of a\u00a0new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD. Gastrointest Endosc 60(4):505\u2013512","journal-title":"Gastrointest Endosc"},{"issue":"6","key":"1207_CR31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier\u00a0JF, Magro\u00a0F, Abreu\u00a0C, Armuzzi\u00a0A, Ben-Horin\u00a0S, Chowers\u00a0Y, Cottone\u00a0M, de Ridder\u00a0L, Doherty\u00a0G, Ehehalt\u00a0R et al (2014) Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J\u00a0Crohns Colitis 8(6):443\u2013468","journal-title":"J Crohns Colitis"},{"issue":"10080","key":"1207_CR32","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro\u00a0R, Mehandru\u00a0S, Allen\u00a0PB, Peyrin-Biroulet\u00a0L, Colombel\u00a0JF (2017) Ulcerative colitis. Lancet 389(10080):1756\u20131770","journal-title":"Lancet"},{"issue":"11","key":"1207_CR33","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/ecco-jcc\/jjx089","volume":"11","author":"MM Estevinho","year":"2017","unstructured":"Estevinho\u00a0MM, Afonso\u00a0J, Rosa\u00a0I, Lago\u00a0P, Trindade\u00a0E, Correia\u00a0L, Dias\u00a0CC, Magro\u00a0F, GEDII (2017) A systematic review and meta-analysis of 6\u2011thioguanine nucleotide levels and clinical remission in inflammatory bowel disease. J\u00a0Crohns Colitis 11(11):1381\u20131392","journal-title":"J Crohns Colitis"},{"issue":"23","key":"1207_CR34","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts\u00a0P, Sandborn\u00a0WJ, Feagan\u00a0BG, Reinisch\u00a0W, Olson\u00a0A, Johanns\u00a0J, Travers\u00a0S, Rachmilewitz\u00a0D, Hanauer\u00a0SB, Lichtenstein\u00a0GR et\u00a0al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N\u00a0Engl J Med 353(23):2462\u20132476","journal-title":"N Engl J Med"},{"issue":"2","key":"1207_CR35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner\u00a0J, Lemaitre\u00a0M, Carrat\u00a0F, Zureik\u00a0M, Carbonnel\u00a0F, Dray-Spira\u00a0R (2018) Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 155(2):337\u2013346e10","journal-title":"Gastroenterology"},{"issue":"13","key":"1207_CR36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands\u00a0BE, Peyrin-Biroulet\u00a0L, Loftus\u00a0EV Jr., Danese\u00a0S, Colombel\u00a0JF, Toruner\u00a0M, Jonaitis\u00a0L, Abhyankar\u00a0B, Chen\u00a0J, Rogers\u00a0R et al (2019) Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N\u00a0Engl J Med 381(13):1215\u20131226","journal-title":"N Engl J Med"},{"issue":"10","key":"1207_CR37","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","volume":"50","author":"WJ Sandborn","year":"2019","unstructured":"Sandborn\u00a0WJ, Panes\u00a0J, Sands\u00a0BE, Reinisch\u00a0W, Su\u00a0C, Lawendy\u00a0N, Koram\u00a0N, Fan\u00a0H, Jones\u00a0TV, Modesto\u00a0I et\u00a0al (2019) Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther 50(10):1068\u20131076","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1207_CR38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","volume":"48","author":"JA Eaden","year":"2001","unstructured":"Eaden\u00a0JA, Abrams\u00a0KR, Mayberry\u00a0JF (2001) The risk of colorectal cancer in ulcerative colitis: a\u00a0meta-analysis. Gut 48(4):526\u2013535","journal-title":"Gut"},{"issue":"7","key":"1207_CR39","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ajg.2015.65","volume":"110","author":"CH Choi","year":"2015","unstructured":"Choi\u00a0CH, Rutter\u00a0MD, Askari\u00a0A, Lee\u00a0GH, Warusavitarne\u00a0J, Moorghen\u00a0M, Thomas-Gibson\u00a0S, Saunders\u00a0BP, Graham\u00a0TA, Hart\u00a0AL (2015) Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterology 110(7):1022\u20131034","journal-title":"Am J Gastroenterology"},{"key":"1207_CR40","doi-asserted-by":"publisher","DOI":"10.1055\/a-1482-9273","author":"EF Stange","year":"2021","unstructured":"Stange\u00a0EF (2021) Steroid-refractory ulcerative colitis: a\u00a0critical review of national and international guideline recommendations. Z\u00a0Gastroenterol. https:\/\/doi.org\/10.1055\/a-1482-9273","journal-title":"Z Gastroenterol"},{"issue":"4","key":"1207_CR41","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","volume":"48","author":"S Singh","year":"2018","unstructured":"Singh\u00a0S, Fumery\u00a0M, Sandborn\u00a0WJ, Murad\u00a0MH (2018) Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease. Aliment Pharmacol Ther 48(4):394\u2013409","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1207_CR42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","volume":"67","author":"D Laharie","year":"2018","unstructured":"Laharie\u00a0D, Bourreille\u00a0A, Branche\u00a0J, Allez\u00a0M, Bouhnik\u00a0Y, Filippi\u00a0J, Zerbib\u00a0F, Savoye\u00a0G, Vuitton\u00a0L, Moreau\u00a0J et al (2018) Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 67(2):237\u2013243","journal-title":"Gut"},{"key":"1207_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006792.pub2","author":"EI Benchimol","year":"2008","unstructured":"Benchimol\u00a0EI, Seow\u00a0CH, Steinhart\u00a0AH, Griffiths\u00a0AM (2008) Traditional corticosteroids for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006792.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"1207_CR44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","volume":"2","author":"CY Ponsioen","year":"2017","unstructured":"Ponsioen\u00a0CY, de Groof\u00a0EJ, Eshuis\u00a0EJ, Gardenbroek\u00a0TJ, Bossuyt\u00a0PMM, Hart\u00a0A, Warusavitarne\u00a0J, Buskens\u00a0CJ, van Bodegraven\u00a0AA, Brink\u00a0MA et al (2017) Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: a\u00a0randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2(11):785\u2013792","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1207_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000067.pub3","author":"N Chande","year":"2015","unstructured":"Chande\u00a0N, Patton\u00a0PH, Tsoulis\u00a0DJ, Thomas\u00a0BS, MacDonald\u00a0JK (2015) Azathioprine or 6\u2011mercaptopurine for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD000067.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1207_CR46","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.eclinm.2020.100271","volume":"20","author":"OH Nielsen","year":"2020","unstructured":"Nielsen\u00a0OH, Steenholdt\u00a0C, Juhl\u00a0CB, Rogler\u00a0G (2020) Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 20:100271","journal-title":"EClinicalMedicine"},{"issue":"12","key":"1207_CR47","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","volume":"25","author":"DR Berg","year":"2019","unstructured":"Berg\u00a0DR, Colombel\u00a0JF, Ungaro\u00a0R (2019) The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis 25(12):1896\u20131905","journal-title":"Inflamm Bowel Dis"},{"issue":"10182","key":"1207_CR48","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","volume":"393","author":"BD Ye","year":"2019","unstructured":"Ye\u00a0BD, Pesegova\u00a0M, Alexeeva\u00a0O, Osipenko\u00a0M, Lahat\u00a0A, Dorofeyev\u00a0A, Fishman\u00a0S, Levchenko\u00a0O, Cheon\u00a0JH, Scribano\u00a0ML et al (2019) Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet 393(10182):1699\u20131707","journal-title":"Lancet"},{"issue":"1","key":"1207_CR49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/14712598.2020.1811849","volume":"21","author":"TL Parigi","year":"2021","unstructured":"Parigi\u00a0TL, D\u2019Amico\u00a0F, Peyrin-Biroulet\u00a0L, Danese\u00a0S (2021) Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opin Biol Ther 21(1):37\u201346","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"1207_CR50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn\u00a0WJ, Baert\u00a0F, Danese\u00a0S, Krznaric\u00a0Z, Kobayashi\u00a0T, Yao\u00a0X, Chen\u00a0J, Rosario\u00a0M, Bhatia\u00a0S, Kisfalvi\u00a0K et\u00a0al (2020) Efficacy and safety of vedolizumab subcutaneous formulation in a\u00a0randomized trial of patients with ulcerative colitis. Gastroenterology 158(3):562\u2013572e12","journal-title":"Gastroenterology"},{"issue":"10","key":"1207_CR51","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","volume":"3","author":"BG Feagan","year":"2018","unstructured":"Feagan\u00a0BG, Panes\u00a0J, Ferrante\u00a0M, Kaser\u00a0A, D\u2019Haens\u00a0GR, Sandborn\u00a0WJ, Louis\u00a0E, Neurath\u00a0MF, Franchimont\u00a0D, Dewit\u00a0O et al (2018) Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study. Lancet Gastroenterol Hepatol 3(10):671\u2013680","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"1207_CR52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/neurolint12030016","volume":"12","author":"G Lassiter","year":"2020","unstructured":"Lassiter\u00a0G, Melancon\u00a0C, Rooney\u00a0T, Murat\u00a0AM, Kaye\u00a0JS, Kaye\u00a0AM, Kaye\u00a0RJ, Cornett\u00a0EM, Kaye\u00a0AD, Shah\u00a0RJ et\u00a0al (2020) Ozanimod to treat relapsing forms of multiple sclerosis: a comprehensive review of disease, drug efficacy and side effects. Neurol Int 12(3):89\u2013108","journal-title":"Neurol Int"},{"issue":"10292","key":"1207_CR53","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan\u00a0BG, Danese\u00a0S, Loftus\u00a0EV Jr., Vermeire\u00a0S, Schreiber\u00a0S, Ritter\u00a0T, Fogel\u00a0R, Mehta\u00a0R, Nijhawan\u00a0S, Kempinski\u00a0R et al (2021) Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a\u00a0phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet 397(10292):2372\u20132384","journal-title":"Lancet"},{"issue":"8","key":"1207_CR54","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn\u00a0WJ, Ghosh\u00a0S, Panes\u00a0J, Schreiber\u00a0S, D\u2019Haens\u00a0G, Tanida\u00a0S, Siffledeen\u00a0J, Enejosa\u00a0J, Zhou\u00a0W, Othman\u00a0AA et\u00a0al (2020) Efficacy of upadacitinib in a\u00a0randomized trial of patients with active ulcerative colitis. Gastroenterology 158(8):2139\u20132149e14","journal-title":"Gastroenterology"},{"issue":"10","key":"1207_CR55","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1055\/a-1234-8079","volume":"58","author":"A Stallmach","year":"2020","unstructured":"Stallmach\u00a0A, Sturm\u00a0A, Blumenstein\u00a0I, Helwig\u00a0U, Koletzko\u00a0S, Lynen\u00a0P, Schmidt\u00a0C, Dignass\u00a0A, Kucharzik\u00a0T, Collaborators (2020) Addendum to S3-guidelines Crohn\u2019s disease and ulcerative colitis: management of patients with inflammatory bowel disease in the COVID-19 pandemic\u2014open questions and answers. Z\u00a0Gastroenterol 58(10):982\u20131002","journal-title":"Z Gastroenterol"},{"issue":"3","key":"1207_CR56","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","volume":"161","author":"N Khan","year":"2021","unstructured":"Khan\u00a0N, Mahmud\u00a0N (2021) Effectiveness of SARS-CoV\u20112 vaccination in a\u00a0veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology 161(3):827\u2013836","journal-title":"Gastroenterology"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01207-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01207-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01207-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T12:06:48Z","timestamp":1638965208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01207-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01207-6","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"26 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.F.\u00a0Manthey gibt an, dass eine Beratert\u00e4tigkeit und Referentent\u00e4tigkeit bei Ferring besteht. S.\u00a0Huber gibt an, dass eine Beratert\u00e4tigkeit und Referentent\u00e4tigkeit bei AbbVie, Falk, Ferring und Janssen besteht. D.\u00a0Reher gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}